Covers a composition comprising the combination of 1-dopa and 2-imino-5-phenyl-4-oxazolidinone and salts thereof and use of said composition in treating Parkinson's disease.
Small organic molecules capable of effecting a "pharmacological trabeculocanalotomy" in an eye by means of reducing juxtacanalicular meshwork as a barrier to outflow of aqueous. The small organic molecules increase Gelatinase A activity in ocular cells by increasing cell membrane expression of membrane-type matrix metalloproteinases (MT-MMPs) to increase aqueous outflow as a treatment for primary open angle glaucoma.
